OptiBiotix Health PLC (LON:OPTI) shares were buoyed on Wednesday after it launched its SlimBiome Medical weight management product in the UK market.
The company, which develops compounds to help tackle obesity, high cholesterol and diabetes, said SlimBiome would be available to buy from its website in boxes of 30 single-dose sachets from 29 April.
READ: OptiBiotix Health gets licence to manufacture weight management product SlimBiome in India
Opti also reported prelaunch sales to Bridge4 Health Ltd, a health and well-being centre based in Leicester, which would conduct a three-month field trial of the product to support weight loss among its gym members.
Fred Narbel, managing director of Opti’s Prebiotics division, said the UK launch would allow the group to “build early revenues at high margin through direct consumer sales”.
The launch follows SlimBiome receiving a CE mark in November last year, which allows it to be freely marketed within the European Economic Area (EEA).
READ: OptiBiotix surges as SlimBiome granted CE mark and medical device status
Since receiving the mark, the company has signed a slew of distribution deals for countries including Italy, Spain, Greece, Cyprus and Bulgaria.
More recently, the group has expanded its international presence, receiving a licence from the Food Standards and Safety Authority India earlier in April to manufacture SlimBiome in the country.
In mid-morning trading, OptiBiotix shares were up 1.7% at 82.9p.
-- Adds share price --